Für Ärzte/Ärztinnen

Ich lege großen Wert auf eine vertrauensvolle Zusammenarbeit mit dem zuweisenden Arzt. Gern stelle ich mich Ihnen auch persönlich vor. Sie erreichen mich unter 0176 52020 181 oder senden Sie mir eine Nachricht, dann rufe ich zurück!

Nachricht senden

Ergänzende Links zu Studien und anderen Dokumenten:

REIZDARM

Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome (IBS).

https://www.ncbi.nlm.nih.gov/pubmed/30611316

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS)

https://www.prnewswire.com/news-releases/launch-of-ibs-smart-an-advancement-in-blood-testing-for-irritable-bowel-syndrome-ibs-announced-by-gemelli-biotech-in-partnership-with-the-medically-associated-science-and-technology-program-mast-at-cedars-sinai-300728775.html

Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

https://www.ncbi.nlm.nih.gov/pubmed/28451914

Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)

https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

IBSchek - The First Clinically Validated Blood Test for IBS with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)

http://www.commdx.com/irritable-bowel-syndrome.html

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

25 % aller Nicht-Antibiotika schädigen Darmbakterien

https://www.ernaehrungsmedizin.blog/2018/03/20/hunderte-medikamente-schaedigen-darmbakterien/

Proton pump inhibitors (PPI) therapy and risk of C. diff. infection: Systematic review and meta-analysis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643276/

FODMAP

Kluyveromyces marxianus-Hefe ermöglicht die Herstellung von FODMAP-armem Vollkornbrot

https://www.ncbi.nlm.nih.gov/pubmed/30166134

Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs

https://www.ncbi.nlm.nih.gov/pubmed/28740352

Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467063/

Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918736/

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/24076059

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/21615553

SIBO

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

https://www.ncbi.nlm.nih.gov/pubmed/21208106

Treatment of SIBO

http://www.townsendletter.com/FebMarch2015/sibo0215_2.html

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach

https://www.ncbi.nlm.nih.gov/pubmed/26780631

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504364/

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

https://www.ncbi.nlm.nih.gov/pubmed/20852272

A 14-day elemental diet is highly effective in normalizing the lactulose breath test

https://www.ncbi.nlm.nih.gov/pubmed/14992438

Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/22523730

Two Independent Networks of Interstitial Cells of Cajal Work Cooperatively with the Enteric Nervous System to Create Colonic Motor Patterns

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153851/

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/20937045

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system (also known as Saccharomyces cerevisiae HANSEN CBS 5926)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027949/

ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth SIBO 2020

ACG_Clinical_Guideline__Small_Intestinal

Adobe Acrobat Dokument 406.0 KB